Whilst these treatments are effective in reducing retinopathy in patients, long-term use of anti-VEGF agents has been linked to eye inflammation and capillary regression of the remaining healthy microvasculature [43] Given the increasing number of patient with diabetes, and the high chance of these patients developing retinopathy [1, 2], there is a significant need to consider alternate potential therapeutic approaches to reduce permeability and vasculogenesis in the retinal microvasculature. The gene discussed is VEGFA; the disease is retinal disorder.